The clinical effectiveness of a combination therapy comprising a TKI and SMO inhibitor combination as an LSC-targeted therapy in CML has yet to be fully determined. The gene discussed is SMO; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.